Concepedia

Larry Ereshefsky

LE

Statistics

Publications

77

Citations

6.1K

H-Index

46

Active since

1981

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

PAREXEL International (United States)

The University of Texas at Austin

Los Angeles Clinical Trials

Austin College

Larry Ereshefsky is an author at The University of Texas at San Antonio Health Science Center specializing in pharmacology, psychopharmacology, and medicine.

Publications per year

1981–2023

77

Publications

77

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

, , +17

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

, , +16

Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications

Dawn I. Velligan, Mei Wang, Pamela M. Diamond et al. · Psychiatric Services · 2007 · 242 citations

, , +17

Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.

Larry Ereshefsky, Stephen R. Saklad, Michael W. Jann et al. · PubMed · 1984 · 230 citations

, , +16

Pharmacokinetics and drug interactions: update for new antipsychotics.

Larry Ereshefsky · PubMed · 1996 · 213 citations

, , +17

1–5 of 77